Clinical Trial Update: Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Site After Wound Closure [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Aruba Aloe Formula F-BC-096 for treatment of split-thickness donor-site wounds after wound closure; the study is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wounds

Drugs mentioned

• Aruba Aloe Formula F-BC-096

Snippet

Sponsor: University Hospital, Ghent | Conditions: Wounds | Phase 4 | Status: COMPLETED